{"id":814446,"date":"2025-02-18T16:36:10","date_gmt":"2025-02-18T21:36:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/"},"modified":"2025-02-18T16:36:10","modified_gmt":"2025-02-18T21:36:10","slug":"ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/","title":{"rendered":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET"},"content":{"rendered":"
\n

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open.<\/p>\n

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Date\u00a0<\/td>\nFriday, February 28, 2025<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Time<\/td>\n8:00 a.m. ET<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Toll free (U.S.)\u00a0<\/td>\n800-579-2543<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Conference ID<\/td>\n4860276<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Webcast (live and replay)\u00a0<\/td>\n\n www.anipharmaceuticals.com<\/a>, under the \u201cInvestors\u201d section<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

A replay of the conference call will be available within two hours of the call\u2019s completion and will remain accessible for two weeks by dialing 800-756-0554 and entering access code 4860276.<\/p>\n

\n About ANI Pharmaceuticals, Inc. <\/strong>
\n
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of \u201cServing Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit\u00a0www.anipharmaceuticals.com<\/a>.<\/p>\n

\n Investor Relations Contact:<\/strong>
\n
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com<\/a>
<\/a><\/p>\n

\n SOURCE: ANI Pharmaceuticals, Inc.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date\u00a0 Friday, February 28, 2025 \u00a0 \u00a0 Time 8:00 a.m. ET \u00a0 \u00a0 Toll free (U.S.)\u00a0 800-579-2543 \u00a0 \u00a0 Conference ID 4860276 \u00a0 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 A replay of the conference call … <\/p>\n

Continue reading “ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814446","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date\u00a0 Friday, February 28, 2025 \u00a0 \u00a0 Time 8:00 a.m. ET \u00a0 \u00a0 Toll free (U.S.)\u00a0 800-579-2543 \u00a0 \u00a0 Conference ID 4860276 \u00a0 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 A replay of the conference call … Continue reading "ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T21:36:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET\",\"datePublished\":\"2025-02-18T21:36:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/\"},\"wordCount\":255,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/\",\"name\":\"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=\",\"datePublished\":\"2025-02-18T21:36:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/","og_locale":"en_US","og_type":"article","og_title":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk","og_description":"PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (\u201cANI\u201d or the \u201cCompany\u201d) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date\u00a0 Friday, February 28, 2025 \u00a0 \u00a0 Time 8:00 a.m. ET \u00a0 \u00a0 Toll free (U.S.)\u00a0 800-579-2543 \u00a0 \u00a0 Conference ID 4860276 \u00a0 \u00a0 Webcast (live and replay)\u00a0 www.anipharmaceuticals.com, under the \u201cInvestors\u201d section \u00a0 \u00a0 A replay of the conference call … Continue reading \"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-18T21:36:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET","datePublished":"2025-02-18T21:36:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/"},"wordCount":255,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/","name":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=","datePublished":"2025-02-18T21:36:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDM3MyM2NzU2NjMzIzIwMTkyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2024-financial-results-on-february-28-2025-at-800-a-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814446"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814446\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}